Skip to content Skip to site navigation Skip to local navigation
Department of Health

Medical Services Advisory Committee

  • MSAC
  • About MSAC
    • About MSAC
    • MSAC Process Framework
    • MSAC Executive Terms of Reference
    • MSAC Terms of Reference
    • MSAC Membership
    • ESC Terms of Reference
    • ESC Membership
    • PASC Terms of Reference
    • PASC Membership
    • Frequently Asked Questions
  • MSAC Meetings
    • Meetings
  • Public Funding
    • How to Apply for Public Funding
  • Forms Templates & Guidelines
    • Assessment Groups
    • Applicants
  • Guidelines Review
    • Guidelines Review
    • Guidelines Review Webinars
  • MSAC Applications
    • Application Page
  • Utilisation Monitoring Process
  • You are here:
  • Medical Services Advisory Committee /
  • MSAC Meetings /
  • Meetings /

PASC - Meeting 8 December 2017

Page last updated: 28 November 2017

PICO Advisory Sub-Committee - Applications Considered


1491 - Vagus Nerve Stimulation (VNS) for the treatment of treatment resistant depression (TRD)

1498 - Serum soluble transferrin receptor

1505 - Programmed cell death ligand 1 (PD L1) testing in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) to determine eligibility for durvalumab monotherapy or durvalumab/tremelimumab combination therapy (co dependent).

1506 - Programmed cell death ligand 1 (PD-L1) testing to determine PBS access to durvalumab or durvalumab/tremelimumab as 1st line therapy for patients with unresectable Stage IV urothelial cancer

1507 - Germline BRCA mutation testing to determine eligibility for olaparib treatment in patients with locally advanced or metastatic HER2 negative breast cancer (either hormone receptor positive or triple negative)

1508 - Pembrolizumab (MK-3475) in Mismatch Repair Deficient (dMMR) Stage IV Solid tumours other than colorectal cancer

1510 - Emicizumab for routine prophylaxis to prevent bleeding or reduce the frequency of bleeding episodes in patients with Haemophilia A (congenital Factor VIII deficiency) with Factor VIII inhibitors.

1511 - Extended half-life (EHL) blood clotting factors VIII + IX
Listen
  • MSAC Meetings
  • Meetings
    • MSAC – ESC Calendar Key Dates
    • PASC Calendar Key Dates
    • Co-dependent Technologies
  • MSAC Email Bulletin


  • Feedback
Provide feedback

Comments will be used to improve web content and will not be responded to.

Real person check

This form uses a CAPTCHA to ensure that it is submitted by a person, instead of a machine or automated software.


Privacy statement

Your feedback has been submitted

Thank you for taking the time to provide feedback. It will be used to make improvements to this website.

Medical Services Advisory Committee

Medical Services Advisory Committee

© Commonwealth of Australia
ABN: 83 605 426 759

MBS Information

  • MBS Online
  • Legislation that covers the MBS
  • About MBS Factsheets
  • MBS Review

HTA Information

  • What is HTA
  • Australian Government HTA processes

Useful Links

  • MBS Online
  • PBS
  • PBAC
  • PLAC
  • Health Technology Reference Group
  • Healthier Medicare
  • MBS Review
  • TGA
  • HTA Conflict of Interest Guide

About

  • Copyright
  • Linking to this site
  • Accessibility
  • Disclaimer
  • Privacy
  • What is RSS?
  • Contact Us